ACADIA Pharmaceuticals Inc ACAD:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
28.25 0.10   0.36%--1,262,2671.9M
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 1/17/2018

Latest News Headlines for ACADIA Pharmaceuticals Inc

No News for ACADIA Pharmaceuticals Inc

Peers Information HelpACAD ACADIA Pharmaceuticals Inc vs. Peers

ACADIA Pharmaceuticals Inc
Agios Pharmaceuticals Inc
Sarepta Therapeutics Inc
Ligand Pharmaceuticals Inc.
FibroGen Inc
ACADIA Pharmaceuticals Inc
Agios Pharmaceuticals Inc
Sarepta Therapeutics Inc
Ligand Pharmaceuticals Inc.
FibroGen Inc
ACADIA Pharmaceuticals Inc
Agios Pharmaceuticals Inc
Sarepta Therapeutics Inc
Ligand Pharmaceuticals Inc.
FibroGen Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open28.43
Previous Close28.25
Day High28.47
Day Low28.05
52 Week High10/5/2017 | 41.20
52 Week Low6/8/2017 | 25.06
% Off 52 Week High-31.43%
% Off 52 Week Low12.73%
Beta (5 Yr)3.5
Volatility Avg1/17/2018 | 41.47
10-Day Avg. Volume1,945,827
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2017 | -2.46
P/E Ratio9/30/2017 | --
Market CapMid Cap | 3.46B
Shares Outstanding122.40M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short9.90M
Short Ratio7.0
Short % of Float8.10%
As of 12/29/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.